TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03607955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVB-S6-500
Description: AVB-S6-500 is supplied by Aravive Biologics

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Commercially available

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Commercially available

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tissue from Diagnostic Laparoscopy
Description: -For patients scheduled to undergo a diagnostic laparoscopy for tissue diagnosis prior to neoadjuvant chemotherapy, a tissue biopsy section from the ovary or an intra-abdominal implant will be performed

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tissue from Core biopsy
Description: -Standard of care procedure but research specimens will be collected
Study: NCT05422001

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (saline)
Description: Isotonic Saline
Study: NCT03607955

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interval Debulking
Description: * Standard of Care~* Research tissue samples will be collected

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood
Description: -Before initiation of neoadjuvant chemotherapy and at the time of interval debulking surgery either pre-operatively, intraoperatively, or post-operatively.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ascites collection
Description: -A total of 25-100ml of ascites will be collected prior to chemotherapy treatment, if available.
Study: NCT05031052

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: End-ischemic normothermic oxygenated machine perfusion
Description: Application of end-ischemic normothermic oxygenated machine perfusion at physiological temperatures for 4 hours.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Static cold storage
Description: Immediate implantation of kidney allograft after conventional and static preservation on ice
Study: NCT05581069

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STEPS
Description: STEPS is a psychosocial intervention that targets self-determination, self-regulation, and self-knowledge to improve functional independence and quality of life in adults.
Study: NCT06448624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ampicillin sulbactam 3 days
Description: Ampicillin sulbactam 1.5 gram IV TID for 3 days after CIED implantation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 3 days
Description: Placebo for 3 days after CIED implantation
Study: NCT04966949

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lateral prostate capsule sparing or neurovascular bundles sparing
Description: When resect the bladder and prostate, the lateral prostate capsule or neurovascular bundles will be preserved.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lateral prostate capsule sparing or neurovascular bundles sparing
Description: When resect the bladder and prostate, the lateral prostate capsule or neurovascular bundles will be preserved.
Study: NCT06082856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Induction of general anesthesia by administration of dexmedetomidine 0.5µg/Kg (maximum dose 50 µg) in titration by bolus of 10µg intravenously over 5 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: Induction of general anesthesia by administration of sufentanil 0.25µg/Kg (maximum dose 20 µg) intravenously at anesthetic induction.
Study: NCT05525559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ET0038
Description: ET0038 for oral administration
Study: NCT06038422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTP regimen
Description: Refractory/recurrent hemophagocytic lymphohistiocytosis patients will be treated with GTP regimen (Emapalumab+Teniposide+Methylprednisolone)
Study: NCT05791227

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Sonographer Evaluation
Description: A sonographer will assess measurements of left ventricular diameter during diastole (LVIDd), intraventricular septum thickness during diastole (IVSd) and left ventricular posterior wall thickness during diastole (LVPWd).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: AI Evaluation
Description: An AI model will assess measurements of left ventricular diameter during diastole (LVIDd), intraventricular septum thickness during diastole (IVSd) and left ventricular posterior wall thickness during diastole (LVPWd).
Study: NCT04685876

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine
Description: 4-quadrant TAP block with liposomal bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plain bupivacaine
Description: 4-quadrant TAP block with plain bupivacaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: placebo (normal saline).
Study: NCT06267612

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Corheart 6 Left Ventricular Assist System
Description: Implantation of left ventricular assist device for hemodynamic support
Study: NCT06014060

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 24 Months DAPT
Description: All subjects will receive co-administration of aspirin (100 mg/day) and clopidogrel (75 mg/day) for 12 months after randomization.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 12 Months DAPT
Description: All subjects will receive aspirin (100 mg/day) monotherapy without co-administration of clopidogrel for 12 months after randomization.
Study: NCT04751487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itepekimab SAR440340
Description: Pharmaceutical form: solution for injection in pre-filled syringe Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itepekimab SAR440340
Description: Pharmaceutical form: solution for injection in pre-filled syringe Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itepekimab SAR440340
Description: Pharmaceutical form: solution for injection in pre-filled syringe Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: solution for injection in pre-filled syringe Route of administration: subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: solution for injection in pre-filled syringe Route of administration: subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: solution for injection in pre-filled syringe Route of administration: subcutaneous
Study: NCT06009055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: 0.3mg/kg，injection completed in 30 seconds

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: 2mg/kg，injection completed in 30 seconds
Study: NCT04957121

Intervention type: OTHER
Intervention: on-hours
Description: If the begin time of anesthesia was between 8:00 to 17:59, it was defined as on-hours.

Intervention type: OTHER
Intervention: off-hours
Description: If the start time of anesthesia was between 18:00 to 7:59 or the end time of anesthesia was later than 20:00, it was defined as off-hours.
Study: NCT06457711

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Free diet Group (FDG)
Description: Participants were offered nutritional guidance and were encouraged to adhere to the principles of the Mediterranean diet and follow the dietary recommendations outlined in Harvard's Healthy Eating Plate.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Very low Calorie Ketogenic Diet Group (VLCKDG)
Description: Participants were offered nutritional guidance and were encouraged to adhere to the principles of the very low-calorie ketogenic diet (VLCKD) protocol

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent Fasting Group (IFG)
Description: Participants were offered nutritional guidance and were encouraged to adhere to the principles of the intermittent fasting schedule
Study: NCT04875052

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: Whole Body Vibration
Description: Whole body vibration will be delivered using a commercially available device at a frequency of 30Hz and acceleration of 2g for 1 minute a total of 6 times with 2 minutes of rest between exposures.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: Local Muscle Vibration
Description: Local muscle vibration will be delivered using a prototype device at a frequency of 30Hz and acceleration of 2g for 1 minute a total of 6 times with 2 minutes of rest between exposures.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard ACL Rehabilitation
Description: Patients will complete a standard of care rehabilitation emphasizing restoration of early weight bearing, range of motion, quadriceps function, balance, and neuromuscular control.
Study: NCT06409247

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: iExposure
Description: There will be 4 treatment sessions, covering the iExposure intervention. The intervention and assessment process is entirely self-guided. Each session will last approximately 60 minutes. Participants will complete 10 mock-interaction trials for each session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iExposure plus attention guidance
Description: The attention guidance condition consists of two unique components in addition to the standard iExposure intervention: (1) the intervention rationale will include information about the importance of visually attending to the faces of the audience; (2) participants will be given a target audience member to focus their gaze on during each impromptu response. They will be told that they should look at and focus on the target audience member for the whole response. In each progressive session the number of trials where the participant is directed to focus on an uninterested audience member will increase.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iExposure plus attention control
Description: The attention control condition consists of two unique components in addition to the standard iExposure intervention (1) the intervention rationale will include information about the importance of developing attention control; (2) participants will be given a central region of the screen (non-audience member) to focus on. They will be told that they should look at and focus on the central region for the whole response.
Study: NCT04952220

Intervention type: DEVICE
Intervention: ultrasound
Description: Describe the sonographic abnormalities observed at Day 0, Day 10, 6 weeks, 3 months, 6 months, during native septic arthritis of the knee
Study: NCT05409235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTT166
Description: Participants will receive OTT166 ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTT166
Description: Participants will receive OTT166 ophthalmic solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle control
Description: Participants will receive vehicle control

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle control
Description: Participants will receive vehicle control
Study: NCT05090761

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25% Injectable Solution
Description: Injection of Bupivacaine 0.25% Injectable Solution for SAPB

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 150 mg
Description: Injection of Bupivacaine 0.25% Injectable Solution for SAPB Addition of 150 mg of Magnesium Sulfate as adjuvant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 150 mg, Buprenorphine 300 mcg
Description: Injection of Bupivacaine 0.25% Injectable Solution for SAPB Addition of 150 mg of Magnesium Sulfate and 300mcg Buprenorphine as adjuvants
Study: NCT04906642

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Next Science
Description: Solution is a clear, colorless, aqueous solution that is used to remove debris, including microorganisms, from wounds via hydrodynamic shear across the wound. This aids in the removal of foreign material such as, microorganisms, dirt, and debris.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Normal Saline will be used in place of Next Science for irrigation
Study: NCT05339607

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thermal ablation of resection margins by STSC and biliary orifice by cystotome.
Description: Patients who are eligible will undergo thermal ablation of the resection margins.
Study: NCT05024747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NicoDerm CQ patch (GSK Dungarvan)
Description: A single patch of a NicoDerm CQ (GSK Dungarvan) 21 mg per system of 22 centimeter square (cm\^2) surface area will be placed topically.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NicoDerm CQ (Alza)
Description: A single patch of a NicoDerm CQ (Alza) 21 mg/system of 22 cm\^2 surface area will be placed topically.
Study: NCT06409273

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hybrid course on medical thesis for post graduates general practice students
Description: Students randomised to the intervention group will log on to interactive online teaching for a maximum time of 2.5 hours, and then follow face-to-face socio-constructivist teaching in small groups (n=22 max), building on the knowledge they have acquired. The aim of this peer-to-peer face-to-face teaching is to develop problem-solving skills.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face teaching on medical thesis for post graduates general practice students
Description: Students randomised to the control group will be taught entirely face-to-face in small groups (n=22 max). The course duration and teaching objectives are identical to those of the intervention group. Student consent and randomization will be carried out on the morning of the course to avoid contamination and attrition bias.
Study: NCT04908592

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Patients will receive dexamethasone 8 mg diluted in 100 ml 0.9% normal saline (NS) IVI over 15 min 2 h preoperatively.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive 100 ml 0.9% normal saline (NS) IVI over 15 min 2 h preoperatively.
Study: NCT06058013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMRA-335140
Description: Participants will receive NMRA-335140 at a dose of 80 mg QD, orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally
Study: NCT04982289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1830
Description: Administered as an SC infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1830
Description: Administered as an SC infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1830
Description: Administered as an SC infusion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as an SC infusion.
Study: NCT05924724

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flash Glucose Monitoring
Description: The FGM is a non-invasive device typically worn on the upper arm, designed to continuously measure blood glucose levels without the need for fingerstick capillary measurements.
Study: NCT05519748

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online psychoeducational program
Description: The intervention group will receive an online psychoeducational program for 8 weeks. The psychoeducation package consists of 16 different sets of reading materials and post-session writing/reflection exercises, which will be delivered to the participants twice a week.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Online psychoeducational program
Description: The intervention group will receive an online psychoeducational program for 8 weeks. The psychoeducation package consists of 16 different sets of reading materials and post-session writing/reflection exercises, which will be delivered to the participants twice a week.
Study: NCT06472934

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement in the absence of B-blocker treatment
Description: Transcatheter aortic valve replacement (TAVR) is performed in patients that temporarily pause B-blocker treatment.

Intervention type: OTHER
Group type: OTHER
Intervention: Transcatheter aortic valve replacement
Description: Transcatheter aortic valve replacement (TAVR) is performed in patients that do not temporarily pause B-blocker treatment.
Study: NCT05819775

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL312
Description: Fully human immunoglobulin G subclass 4/lambda recombinant inhibitor monoclonal antibody administered subcutaneously (SC)
Study: NCT06056505

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: partial kidney nephrectomy
Description: surgery for partial nephrectomy
Study: NCT04935476

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapsone 85 mg PO BID
Description: Participants will receive standard of care and study medication Dapsone 85 mg per os (PO) twice daily for 21 days. If a dose is missed, it will not be replaced.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 85 mg PO BID
Description: Placebo oral tablet, twice daily for 21 days.
Study: NCT05861791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: opioid group receives only fentanyl citrate 1200mcg for continuous infusion drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketorolac tromethamine with nefopam hydrochloride
Description: non-opioid group receives ketorolac tromethamine 150mg with nefopam hydrochloride 100mg for continuous infusion drug
Study: NCT05993247

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics capsule
Description: Subjects will take a probiotics combination capsule (Bacillus Subtilis 150 mg /Clostridium Burtyricum Toa 150 mg /Saccharomyces Boulardii 113 mg) three times a day for 8 weeks in combination with NSAIDs

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Subjects will take a placebo capsule identical in shape and size to probiotics capsule three times a day for 8 weeks in combination with NSAIDs
Study: NCT06056505

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: partial kidney nephrectomy
Description: surgery for partial nephrectomy
Study: NCT05970991

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Online Training (BOLT) for measurement-based care (MBC)
Description: Brief Online Training (BOLT) for measurement-based care (MBC) is a series of 4 interactive, self-paced, online training modules that takes approximately 75 - 120 minutes to complete. Clinicians are trained on the core functions, procedures, and best practice approaches for delivering MBC in the school mental health setting. MBC is the systematic collection of patient-reported data to support collaborative clinical decision-making from intake to termination.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Online Training (BOLT) for measurement-based care (MBC)
Description: Brief Online Training (BOLT) for measurement-based care (MBC) is a series of 4 interactive, self-paced, online training modules that takes approximately 75 - 120 minutes to complete. Clinicians are trained on the core functions, procedures, and best practice approaches for delivering MBC in the school mental health setting. MBC is the systematic collection of patient-reported data to support collaborative clinical decision-making from intake to termination.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Implicit Bias Reduction and Neutralization Training (VIBRANT)
Description: The Virtual Implicit Bias Reduction and Neutralization Training (VIBRANT) is a brief (45-minute), self-paced, interactive online training module designed to help school-based mental health clinicians understand and manage their implicit bias in clinical interactions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Live Post-Training Consultation
Description: Two 1-hour long small group consultation sessions with an expert consultant designed as additional opportunities to support knowledge elaboration and skills generalization.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Live Post-Training Consultation
Description: Two 1-hour long small group consultation sessions with an expert consultant designed as additional opportunities to support knowledge elaboration and skills generalization.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asynchronous Discussion Board
Description: An expert facilitated online Discussion Board for additional opportunities of knowledge clarification, practice reinforcement, and community building to support implementation sustainment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Asynchronous Discussion Board
Description: An expert facilitated online Discussion Board for additional opportunities of knowledge clarification, practice reinforcement, and community building to support implementation sustainment.
Study: NCT05011513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07321332
Description: PF-07321332 (tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir (capsule)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (tablet)
Study: NCT06056505

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DaVinci Robot
Description: device to perform the surgery for partial nephrectomy (not the intervention of interest)
Study: NCT06095778

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active rTMS
Description: 2 sessions with 1800 pulses per session and 50min inter-session interval of active rTMS will deliver to the assigned target
Study: NCT06056505

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DaVinci Robot
Description: device to perform the surgery for partial nephrectomy (not the intervention of interest)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Innersight 3D software
Description: investigational product to generate the 3D model